DMEK Surgery: Restoring Clear Vision With Precision Corneal Transplantation
What Is DMEK and How Does It Work?
DMEK is a partial-thickness corneal transplant that targets one specific layer of the cornea: the endothelium. Understanding what this layer does and why replacing it so precisely matters helps explain why DMEK has become a preferred approach for treating certain forms of corneal disease.
The cornea is the clear, dome-shaped tissue at the very front of the eye that focuses incoming light. Its innermost layer, called the endothelium, functions like a pump, continuously removing excess fluid to keep the cornea thin, clear, and transparent. When endothelial cells are damaged or lost, fluid builds up inside the cornea and it begins to swell. This swelling causes blurry vision, glare, and in more advanced cases, pain.
DMEK transplants only the Descemet membrane and the endothelial cell layer attached to it. This tissue is extraordinarily thin, approximately 15 microns, which is a fraction of the thickness of a human hair. Because DMEK leaves all the healthy outer layers of the cornea completely untouched, recovery is smoother and the eye heals more like its natural self than with older, full-thickness transplants.
Full-thickness corneal transplants, known as penetrating keratoplasty (PK), replace the entire cornea and require multiple stitches, longer healing times, and carry a higher risk of rejection. DMEK, by contrast, is performed through a small incision and typically requires no sutures to hold the graft in place. Patients tend to experience faster visual recovery and a significantly lower rejection rate compared to full-thickness transplants.
Surgical techniques for DMEK continue to evolve. Improvements in tissue preparation, dye-assisted visualization of the graft during surgery, and precision surgical instruments have made the procedure safer and more consistently successful. These refinements have expanded the range of patients who can benefit from the procedure.
Who Is a Candidate for DMEK?
DMEK is specifically designed for patients whose vision loss is caused by endothelial failure rather than disease affecting the outer layers of the cornea. Your Cornea Specialist will perform a thorough evaluation of your corneal health, overall eye history, and vision goals to determine whether DMEK is the right option for you.
Several conditions can damage or deplete endothelial cells to the point where a transplant becomes necessary. The most common include the following.
- Fuchs' endothelial corneal dystrophy, a progressive inherited condition that gradually destroys endothelial cells and is among the most common reasons patients need DMEK
- Bullous keratopathy, chronic corneal swelling that can develop after cataract surgery or other intraocular procedures
- Posterior polymorphous corneal dystrophy, a rare inherited condition causing abnormal endothelial cell behavior and corneal swelling
- Failed previous corneal transplants
- Iridocorneal endothelial (ICE) syndromes, a group of rare conditions involving abnormal endothelial cell growth
Endothelial failure often causes vision that is blurry or hazy first thing in the morning, then slowly clears as the day progresses. This pattern happens because the eyelids trap fluid against the cornea overnight, and daytime evaporation temporarily reduces the swelling. Other common symptoms include glare or halos around lights, especially at night, and a general sense that vision is foggy or washed out. In more advanced cases, the cornea can form painful blisters called bullae.
The best candidates for DMEK are generally adults whose primary eye problem is endothelial cell disease, without significant additional conditions such as advanced glaucoma damage, severe dry eye, or serious retinal disease that would independently limit vision. Age alone is not a barrier. DMEK has been performed successfully in patients ranging from their thirties to their nineties. Your Cornea Specialist will evaluate whether your specific combination of conditions makes DMEK the most appropriate choice.
What Happens During DMEK Surgery?
DMEK is performed as an outpatient procedure by a fellowship-trained Cornea Specialist and typically takes between 45 minutes and one hour. The surgery uses carefully prepared donor tissue obtained from an eye bank, and it requires no large incisions or stitches in most cases.
In the days and weeks before surgery, your Cornea Specialist will perform detailed measurements of your cornea and assess your overall eye health. You may be asked to start antibiotic eye drops before the procedure and to temporarily pause certain medications, such as blood thinners, based on your medical history. On the day of surgery, arrange for a trusted person to drive you home, eat a light meal as instructed, and bring sunglasses for light sensitivity during the ride back.
The surgeon begins by making a small incision at the edge of the cornea and carefully removing the damaged Descemet membrane and endothelial layer from inside the eye. The donor tissue, which is ultra-thin and fragile, is rolled into a small scroll for insertion through that same small opening. Once inside the eye, the surgeon gently unfolds and positions the tissue so it lies flat against the back surface of the cornea. In most cases, no sutures are needed to hold it in place.
After the donor tissue is positioned, the surgeon injects a small air or gas bubble into the front chamber of the eye. This bubble floats upward and presses the new graft firmly against the cornea, acting as a temporary internal support while the tissue bonds naturally over the following days. The bubble gradually absorbs on its own, typically within one to two weeks. Because the bubble must stay in contact with the graft, face-up head positioning after surgery is an important part of the recovery process.
You will receive local anesthesia around the eye along with sedation to keep you comfortable and relaxed throughout the procedure. DMEK is not painful. You may be aware of light or gentle movement but should not feel discomfort. Most patients are pleasantly surprised by how brief and manageable the experience is.
Recovery and Aftercare
Recovery after DMEK is generally faster than recovery from older, full-thickness transplants, and many patients notice meaningful vision improvement within the first few weeks. Following your Cornea Specialist's instructions closely during recovery is one of the most important factors in achieving the best possible outcome.
During the initial recovery period, face-up positioning is critical. Your surgeon will advise you to lie flat on your back as much as possible, typically around 45 to 50 minutes out of every waking hour, to keep the air bubble pressed against the graft while it adheres. Your eye may feel scratchy or sensitive to light during this time, but these sensations usually ease within a few days. Use all prescribed eye drops exactly as directed to prevent infection and manage inflammation.
Face-up positioning is most important during the first 24 to 48 hours, though your surgeon will give you personalized guidance based on how your eye is healing. Strenuous physical activity, heavy lifting, bending at the waist, and swimming should be avoided for at least several weeks. Rubbing the eye should be avoided entirely. Protecting your eye with shields or glasses as recommended helps prevent accidental trauma during the healing period.
Mild discomfort, light sensitivity, and blurry vision are all normal during early recovery. Over-the-counter pain relievers are generally sufficient for any achiness, and the prescribed eye drops help with inflammation and healing. If you experience sudden severe pain, a significant drop in vision, or increasing redness, contact your care team right away, as these may be signs of a complication that needs prompt attention.
Follow-up visits are typically scheduled at one day, one week, one month, three months, six months, and one year after surgery, then annually going forward. Steroid eye drops are prescribed for several months to help prevent graft rejection and should not be stopped without your surgeon's guidance. Vision typically continues to improve and stabilize over the course of six to twelve months as the cornea fully heals and adjusts.
Benefits and Risks of DMEK
DMEK offers excellent visual outcomes for most patients and has become the preferred transplant approach for endothelial disease in many cases. As with any surgical procedure, there are risks involved, though serious complications are uncommon and most issues that do arise can be treated effectively.
The most significant advantages of DMEK over older transplant techniques include a much lower rejection rate, typically around 1 to 2 percent compared to 10 to 15 percent with full-thickness transplants. Most patients achieve 20/25 vision or better over time, and many reach that level within the first month. Because the natural structure of the cornea is largely preserved, vision tends to feel clearer and more natural, with better contrast sensitivity and less glare than patients experienced before surgery.
The most common complication after DMEK is graft detachment, where the donor tissue partially separates from the cornea. This occurs in roughly 20 to 25 percent of cases and is typically corrected with a straightforward in-office procedure called rebubbling, in which a small air bubble is injected to reattach the tissue. Less common complications include elevated eye pressure from steroid drops, primary graft failure (2 to 5 percent of cases), and infection (less than 1 percent). Serious, permanent vision loss is uncommon when aftercare instructions are followed carefully.
The single most important thing patients can do to protect their outcome is to follow every instruction their Cornea Specialist provides, including maintaining proper head positioning, using all eye drops on schedule, and attending every follow-up appointment. Wearing protective eyewear during any activity that carries a risk of eye contact and reporting any unusual changes in vision, pain, or redness promptly all contribute to a successful recovery.
Frequently Asked Questions
The questions below address details and practical decisions that patients commonly want to understand before and after their procedure.
Yes. When a patient has both endothelial disease and a significant cataract, the two procedures are often performed together in what is called a Triple-DMEK or DMEK combined with phacoemulsification and lens implantation. Addressing both problems in a single operation avoids a second surgery and a second recovery period. Your Cornea Specialist will evaluate whether this combined approach is appropriate for your specific situation, taking into account the severity of both conditions.
While the air or gas bubble is present, you will likely see a moving line or shifting shadow in the lower part of your visual field. This is completely expected and does not indicate a problem. The bubble typically absorbs gradually over one to two weeks. During this time, certain activities, including air travel and driving, may be temporarily restricted because of the bubble. Your surgeon will advise you on exactly when each activity can safely resume.
Rebubbling is a brief outpatient procedure in which your surgeon injects a small air bubble into the eye to reattach a graft that has partially separated from the cornea. It is needed in approximately 20 to 25 percent of DMEK cases and is performed with local anesthetic drops in the clinic. Importantly, the need for rebubbling does not necessarily affect your long-term visual outcome. Most patients who undergo rebubbling go on to achieve excellent vision once the graft fully adheres.
No. DMEK is specifically designed to replace only the innermost endothelial layer and does not address problems involving the outer corneal layers, such as surface scarring, shape irregularities, or anterior dystrophies. If your vision problems involve the front layers of the cornea in addition to or instead of the endothelium, your Cornea Specialist will discuss other options, which may include phototherapeutic keratectomy (PTK) or a different type of corneal transplant that targets the affected layers.
DMEK restores the cornea's clarity and ability to function normally, but it does not correct refractive errors such as nearsightedness, farsightedness, or astigmatism. Most patients will still need glasses or contacts for their sharpest vision, particularly for reading. Your prescription will likely change as the eye heals, so a final glasses prescription is usually measured once vision has stabilized, typically at three to six months after surgery.
Some discomfort, light sensitivity, and blurry vision are expected and normal in the first days after surgery. However, certain symptoms require prompt contact with your care team: sudden or significant vision loss, severe eye pain, increasing redness, a sensation that something has changed quickly, or the appearance of flashing lights or new floaters. These could indicate elevated eye pressure, graft detachment, or early signs of rejection, all of which are most effectively treated when caught early. Never wait more than a day to report a symptom you are unsure about.
Specialized Cornea Care at Rhode Island Eye Institute
Our Cornea Specialists, including Dr. Jane Cook, Dr. Elliot Perlman, and Dr. Christopher Newton, bring fellowship-trained expertise, Brown University academic appointments, and decades of combined surgical experience to every patient who walks through our doors. Dr. Perlman, who serves as Director of the Corneal Service at Rhode Island Hospital and Brown Medical School, was the first ophthalmologist in Rhode Island to offer FDA-approved corneal cross-linking, and Dr. Cook completed her fellowship at Bascom Palmer Eye Institute, consistently ranked the number one eye hospital in the United States. If you are experiencing symptoms of corneal endothelial disease or have been told you may need a corneal transplant, we invite you to schedule a consultation with our team and find out whether DMEK is the right path forward for you.